Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
1. Eli Lilly plans to release early orforglipron trial results this year. 2. The drug could be a convenient alternative to injectable weight loss treatments. 3. Market for GLP-1 drugs expected to exceed $150 billion by 2030. 4. Orforglipron may receive regulatory approval as soon as early 2026. 5. The pill could alleviate injection supply issues and expand patient access.